首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   22494篇
  免费   2107篇
  国内免费   477篇
耳鼻咽喉   201篇
儿科学   205篇
妇产科学   552篇
基础医学   2284篇
口腔科学   184篇
临床医学   2364篇
内科学   3011篇
皮肤病学   209篇
神经病学   374篇
特种医学   591篇
外科学   2102篇
综合类   2145篇
一般理论   2篇
预防医学   1672篇
眼科学   54篇
药学   1754篇
  10篇
中国医学   457篇
肿瘤学   6907篇
  2023年   479篇
  2022年   856篇
  2021年   1296篇
  2020年   1012篇
  2019年   1468篇
  2018年   1485篇
  2017年   1210篇
  2016年   847篇
  2015年   894篇
  2014年   1881篇
  2013年   1707篇
  2012年   1221篇
  2011年   1319篇
  2010年   934篇
  2009年   987篇
  2008年   1178篇
  2007年   943篇
  2006年   727篇
  2005年   569篇
  2004年   522篇
  2003年   390篇
  2002年   238篇
  2001年   268篇
  2000年   236篇
  1999年   229篇
  1998年   182篇
  1997年   171篇
  1996年   181篇
  1995年   147篇
  1994年   148篇
  1993年   106篇
  1992年   72篇
  1991年   61篇
  1990年   50篇
  1989年   64篇
  1988年   42篇
  1987年   43篇
  1986年   34篇
  1985年   100篇
  1984年   125篇
  1983年   96篇
  1982年   126篇
  1981年   86篇
  1980年   78篇
  1979年   73篇
  1978年   45篇
  1977年   29篇
  1976年   33篇
  1975年   27篇
  1974年   25篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
超声内镜及CT检查对食管癌术前TN分期的价值   总被引:1,自引:0,他引:1  
目的 评价超声内镜、螺旋CT检查对食管癌术前TN分期的价值.方法 回顾性总结术前EUS、CT判断87例食管癌的分期资料,并与术后病理分期对照.患者均未行化、放疗.环扫超声内镜进行操作,5例轻度狭窄病例扩张后再予EUS分期.结果 EUS T分期总准确率为85.1%,CT无法区分T1、T2.对于N分期,EUS判断探及范围内淋巴结转移的灵敏度为85.0%,高于CT扫描的60.8%;CT探查纵隔淋巴结较EUS全面.EUS与cT联合判断T分期的准确率为85.1%,N分期的准确率为90.8%.结论 EUS判断肿瘤浸润深度准确性高,EUS联合CT可进行更为全面准确的TNM分期.  相似文献   
992.
d'Istria  M.  Fasano  S.  Catuogno  F.  Gaeta  F.  Bucci  L.  Benassai  G.  Mazzeo  F.  Delrio  G. 《Diseases of the colon and rectum》1986,29(4):263-265
Androgen, progesterone and estrogen receptors were analyzed in 12 primary colonic cancers and 16 primary rectal cancers. Androgen and progesterone receptors were positive in some colonic cancers and rectal carcinomas; however, none of the specimens analyzed showed estradiol receptor. This research was performed under CNR Project “Controllo della Crescita Neoplastica”.  相似文献   
993.
复方五味子素B及其成分体外抑制胃癌细胞的增殖   总被引:4,自引:0,他引:4  
目的:筛选复方五味子素组方最佳配比,比较复方五味子素B及其成分对胃癌细胞的增殖抑制作用.方法:采用L_4(2~3)正交设计的方法筛选药物的最佳配比.用MTT的方法观察组方及其成分对胃癌细胞的增殖抑制作用.空白对照组加培养液;阴性对照和阳性对照组分别加DMSO和5-氟尿嘧啶(5-FU).结果:高浓度五味子乙素(100 mg/L)、低浓度芦荟大黄素(50 mg/L)、低浓度黄芪多糖(50 mg/L)组方为复方五味子素B的药物最佳配比.同阴性对照组(0.427±0.018)相比,五味子乙素低浓度(0.296±0.011)和高浓度组(0.260±0.012)、芦荟大黄素低浓度(0.376±0.017)和高浓度组(0.334±0.013),复方五味素B组(0.162±0.007)在波长490 nm处的吸光度A值均显著性降低(P<0.01);增殖抑制率结果显示,五味子乙素低浓度(26.26%±4.65%)和高浓度组(39.11%±5.13%),芦荟大黄素高浓度组(21.78%±3.67%),复方五味素B组(52.06%±9.87%)抑制率均明显增高.结论:合理的中药有效成分组方可能有效提高单纯中药有效成分的作用,将中药有效成分合理组方可能是开发现代化复方中药的有效方法和途径之一.  相似文献   
994.
PURPOSE: This study was designed to compare histologic T and N stages in patients with rectal adenocarcinoma undergoing various neoadjuvant radiotherapy regimens and proctectomy, in an attempt to determine if final histologic stage of the mural tumor predicts nodal status.METHODS: Data were collected from computerized databases at two institutions on 649 consecutive patients who underwent neoadjuvant radiotherapy or chemoradiotherapy and proctectomy for primary adenocarcinoma of the rectum from 1990 to 2002.RESULTS: Five patients were excluded because of incomplete pathology data sets, leaving a study population of 644. Patients underwent neoadjuvant radiotherapy alone (2,000 cGy in 5 fractions, n = 191; or 4,500 cGy in 25 fractions, n = 259) or chemoradiation (4,500 cGy in 25 fractions with concurrent 5-fluorouracil, n = 194). Histologic stage of the remaining mural tumor (ypT) correlated with nodal status (ypN). Lymph nodes harboring metastatic tumor were found in 1 of 42 (2 percent) ypT0 patients, 2 of 45 (4 percent) ypT1 patients, 43 of 186 (23 percent) ypT2 patients, 158 of 338 (47 percent) ypT3 patients, and 16 of 33 (48 percent) ypT4 patients (P < 0.001, chi-squared test). The probability of finding ypN+ disease was 3 of 87 (3 percent) in patients with ypT0-1 residual primary tumors vs. 220 of 557 (39 percent) in patients with ypT2-4 residual primary tumors (P < 0.0001; Fishers exact test).CONCLUSIONS: Nodal metastases are rare in patients whose mural tumor burden shrinks to ypT0-1 after neoadjuvant radiotherapy. If transanal excision is offered to select patients with distal rectal cancer, it is reasonable to select those who have an excellent clinical response to neoadjuvant therapy for transanal excision, and then reserve proctectomy for patients proven to have residual ypT2-4 disease.Read at the meeting of The American Society of Colon and Rectal Surgeons, New Orleans, Louisiana, June 21 to 26, 2003.  相似文献   
995.
PURPOSE Appendiceal adenocarcinomas are very rare. We analyzed contemporary outcomes associated with surgical therapies for these malignancies.METHODS Retrospective outcomes for patients treated at a tertiary academic medical center from 1981 through 2001 were analyzed.RESULTS A total of 36 patients (22 females (61 percent) mean age, 52 years) with appendiceal adenocarcinoma were treated. Eighty-eight percent of patients presented with symptoms of acute appendicitis. Eighteen (50 percent) patients underwent curative resection (7 primary right hemicolectomies, 10 appendectomies + subsequent right hemicolectomy, and 1 appendectomy alone). Mean length of follow-up was 55 months. Overall five-year survival rate was 46 percent. The five-year survival rate after curative resection was 61 percent and after palliative surgery was 32 percent (P < 0.05). Among patients who underwent curative resection, factors associated with improved five-year survival rates included histologic type (79 vs. 32 percent for colonic vs. mucinous types, respectively; P < 0.05), T stage (75 vs. 47 percent for T1 and 2 vs. T3 and 4, respectively; P < 0.05), and tumor grade (100 vs. 46 percent for well-differentiated tumors vs. moderately or poorly differentiated tumors, respectively; P < 0.05).CONCLUSIONS Patients undergoing surgery for appendiceal adenocarcinoma can be stratified according to prognostic variables. The role of adjuvant therapies for patients with poor prognostic factors needs to be evaluated in a multi-institutional setting.Presented at World Congress of Digestive Surgery, Hong Kong, China, December 9 to 11, 2002.  相似文献   
996.
BACKGROUND: Studies have consistently demonstrated that inactive aldehyde dehydrogenase-2 (ALDH2), encoded by ALDH2*1/2*2, is closely associated with alcohol-related carcinogenesis. Recently, the contributions of alcohol dehydrogenase-2 (ADH2) polymorphism to alcoholism, esophageal cancer, and the flushing response have also been described. METHODS: To determine the effects of ALDH2 and ADH2 genotypes in genetically based cancer susceptibility, lymphocyte DNA samples from 668 Japanese alcoholic men more than 40 years of age (91 with and 577 without esophageal cancer) were genotyped and the results were expressed as odds ratios (ORs). This study also tested 82 of the alcoholics with esophageal cancer to determine whether cancer susceptibility is associated with patients' responses to simple questions about current or former flushing after drinking a glass of beer. RESULTS: The frequencies of ADH2*1/2*1 and ALDH2*1/2*2 were significantly higher in alcoholics with, than in those without, esophageal cancer (0.473 vs. 0.289 and 0.560 vs. 0.099, respectively). After adjustment for drinking and smoking, the analysis showed significantly increased cancer risk for alcoholics with either ADH2*1/2*I (OR = 2.03) or ALDH2*1/2*2 (OR = 12.76). For those having ADH2*1/2*1 combined with ALDH2*1/2*2, the esophageal cancer risk was enhanced in a multiplicative fashion (OR = 27.66). Responses to flushing questions showed that only 47.8% of the ALDH2*1/2*2 heterozygotes with ADH2*1/ 2*1, compared with 92.3% of those with ALDH2*1/2*2 and the ADH2*2 allele, reported current or former flushing. Genotyping showed that for alcoholics who reported ever flushing, the questionnaire was 71.4% correct in identifying ALDH2*1/2*2 and 87.9% correct in identifying ALDH2*1/2*1. CONCLUSION: Japanese alcoholics can be divided into cancer susceptibility groups on the basis of their combined ADH2 and ALDH2 genotypes. The flushing questionnaire can predict high risk ALDH2*1/2*2 fairly accurately in persons with ADH2*2 allele, but a reliable screening procedure for the highest risk gene combination (ADH2*1/2*1 and ALDH2*1/2*2) will require further investigation.  相似文献   
997.
Advanced rectal cancer   总被引:3,自引:0,他引:3  
The best treatment of advanced rectal cancer remains uncertain. The aim of this study was to determine the outcome after palliative procedures in patients with advanced rectal cancer. One hundred and three patients treated over a seven-year period were identified, including 30 with local invasion, 18 with local metastases, and 55 with distant metastases. Patients were grouped into two groups: those who underwent palliative resection (68) and those who were treated without rectal resection (55). The nonresected group included patients who underwent diverting colostomies (28) and those who received multimodality therapy without surgery (7). The average age of all patients was 63.1 years. Patients in the nonresected group had more distant disease (68 percent) than the resected group (46 percent). Significant pelvic pain was a more common problem in the nonresected group (15 percent) than in the resected group (4 percent). Similarly, pelvic sepsis was more common in the nonresected group (14 percent) than in the resected group (9 percent). Postoperative mortality was 4.3 percent after palliative resection and 3.8 percent after diverting colostomy. Survival of the resected group at one year was 65 percent and at two years 20 percent. Survival of the nonresected group at one year was 20 percent and at two years 0 percent. Survival in the resected group was significantly (P<.01) better than the nonresected group but probably can be attributed to the more extensive disease generally present in the patients who did not undergo resection. These results suggest that patients with advanced rectal cancers should undergo palliative resection whenever possible because resection decreases pelvic complications and may improve quality of life. Read at meeting of the American Society of Colon and Rectal Surgeons, Anaheim, California, June 12 to 17, 1988.  相似文献   
998.
Effects of purified bullfrog (Rana catesbeiana) LH and FSH on plasma levels of the androgens, testosterone (T), and 5α-dihydrotestosterone (DHT), were studied using adult male bullfrogs. Rana LH was considerably more potent than Rana FSH in stimulating increased plasma androgen levels in hypophysectomized and intact animals. Simultaneous injection of Rana FSH or ovine PRL with Rana LH, over a 10-day period, did not alter the LH-induced increase in plasma androgens. More DHT than T was present in plasma after LH injection. Castration abolished plasma DHT and greatly reduced plasma T. Results indicate that DHT is a major testicular steroid, and that testicular androgen secretion is stimulated primarily by LH in the bullfrog.  相似文献   
999.

Background

Surgical site infections (SSIs) are a major cause of morbidity, mortality, and healthcare costs, and patients undergoing simultaneous colorectal/liver resections are at an especially high SSI risk.

Methods

Data were collected on all patients undergoing synchronous colorectal/liver resection from 2011 to 2016 (n = 424). The intervention, implemented in 2013, included 13 multidisciplinary perioperative components. The primary endpoints were superficial/deep and organ space SSIs. Secondary endpoints were hospital length of stay (LOS) and 30-day readmission rate. To control for changes in SSI rates independent of the intervention, interrupted time series analysis was conducted.

Results

Overall, superficial/deep, and organ space SSIs decreased by 60.5% (p < 0.001), 80.6% (p < 0.001), and 47.6% (p = 0.008), respectively. In the pre-intervention cohort (n = 231), there were 79 (34.2%), 31 (13.4%), and 48 (20.8%) total, superficial/deep, and organs space SSIs, respectively. In the post-intervention cohort (n = 193), there were 26 (13.5%), 5 (2.6%), and 21 (10.9%) total, superficial/deep, and organs space SSIs, respectively. Median LOS decreased from 9 to 8 days (p < 0.001). Readmission rates did not change (p = 0.6). Interrupted time series analysis found no significant trends in SSI rate within the pre-intervention (p = 0.35) and post-intervention (p = 0.55) periods.

Conclusion

In combined colorectal/liver resection patients, implementation of a multidisciplinary care bundle was associated with a 61% reduction in SSIs, with the greatest impact on superficial/deep SSI, and modest reduction in LOS. The absence of trends within each time period indicated that the intervention was likely responsible for SSI reduction. Future efforts should target further reduction in organ space SSI.  相似文献   
1000.

Aims

Hyperinsulinemia is a recognized risk factor for cancer and plays a major role for the increased cancer incidence in diabetic patients. Whether insulin analogs, and particularly long-acting analogs, worsen the pro-cancer effect of excess insulin is still controversial.

Data synthesis

In this paper we summarize the biological bases for the potential detrimental effect of long-acting analogs on cancer cells and review the in vitro and in vivo evidence on this issue.Because of their different molecular structure relative to native insulin, insulin analogs may activate the insulin receptor (IR) and the post receptor pathways differently. Most, but not all, in vitro evidence indicate that long-acting analogs may have a stronger mitogenic potency than insulin on cancer cells. Notably insulin glargine, the most studied long-acting analog, also has a higher affinity for the insulin-like growth factor (IGF)-1 receptor, a potent growth mediator. In vitro observations, however, may not reflect what occurs in vivo when analogs are metabolized to derivatives with a different mitogenic activity. Clinical studies, mostly retrospective and predominantly concerning glargine, provide contrasting results. The only perspective trial found no cancer increase in patients treated with glargine. All these studies, however, have severe weaknesses because of the insufficient evaluation of important factors such as dose administered, length of exposure, patient follow-up duration and site-specific cancer investigation. Moreover, whether cancer promotion is a long-acting analog class characteristic or a specific effect of a single agent is not clear.

Conclusions

In conclusion the carcinogenic risk of long-acting analogs, and specifically glargine, can be neither confirmed nor excluded. A personalized and shared decision, considering all the individual risk factors (metabolic and non-metabolic), is the suggestion for the clinician.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号